The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer.
 
Olatunji B. Alese
Consulting or Advisory Role - AADi; Bristol-Myers Squibb; Pfizer; QED Therapeutics; Seagen; Seagen; Taiho Oncology
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corcept Therapeutics (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); Ipsen (Inst); PCI Biotech (Inst); SynCoreBio (Inst); Taiho Pharmaceutical (Inst); Transcenta (Inst)
 
Maria Diab
Consulting or Advisory Role - Guardant Health; Novartis
 
Olumide B. Gbolahan
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - Exelixis; Incyte; Merck Sharp & Dohme; QED Therapeutics
Speakers' Bureau - OncLive/MJH Life Sciences
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Eisai (Inst); Pfizer (Inst); Zymeworks (Inst)
 
Ashley McCook-Veal
No Relationships to Disclose
 
Walid Labib Shaib
Honoraria - Blueprint Medicines; BMS; Guardant Health; Ipsen; Lexicon; Mylan; Natera; SEAGEN
Research Funding - ArQule (Inst); Basilea (Inst); GlaxoSmithKline (Inst); Lexicon (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Lexicon
 
Christina Wu
Honoraria - Cancer Treament Centers of America; Medscape; Oncology Learning Network; PrecisCA
Consulting or Advisory Role - Array BioPHarma; Daiichi Sankyo/Lilly; Natera; Natera; Nova Research Company; Pfizer; Seagen
Research Funding - Boston Biomedical (Inst); HUTCHMED; InhibRx (Inst); Lycera (Inst); Pfizer; RAPT Therapeutics (Inst); Seagen (Inst); Symphogen (Inst); Vaccinex (Inst)
 
Mehmet Akce
Consulting or Advisory Role - AstraZeneca; Curio Science; Eisai; Eisai; Eisai; Eisai; Exelixis; Genentech; GlaxoSmithKline; Ipsen; Isofol Medical; QED Therapeutics
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Eisai (Inst); IMPAC Medical Systems (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Polaris (Inst); RedHill Biopharma (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); Xencor (Inst)
 
Yuan Liu
No Relationships to Disclose
 
Gregory B. Lesinski
Research Funding - Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Vaccinex (Inst)
 
Bassel F. El-Rayes
No Relationships to Disclose